Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors

NCT02529072 is registered in ClinicalTrials.gov with Gary Archer Ph.D. as lead sponsor.

NCT NCT02529072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02529072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors
Lead sponsor
Gary Archer Ph.D.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
December 30, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, glioblastoma, malignant glioma